$18.28
4.74% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US14843C1053
Symbol
CSTL

Castle Biosciences Inc Stock price

$19.19
-2.08 9.78% 1M
-9.23 32.48% 6M
-7.46 27.99% YTD
-2.34 10.87% 1Y
-26.80 58.27% 3Y
-8.16 29.84% 5Y
-2.21 10.33% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-1.00 4.95%
ISIN
US14843C1053
Symbol
CSTL
Sector

Key metrics

Market capitalization $553.42m
Enterprise Value $286.74m
P/E (TTM) P/E ratio 31.31
EV/FCF (TTM) EV/FCF 6.63
EV/Sales (TTM) EV/Sales 0.86
P/S ratio (TTM) P/S ratio 1.67
P/B ratio (TTM) P/B ratio 1.20
Revenue growth (TTM) Revenue growth 51.09%
Revenue (TTM) Revenue $332.07m
EBIT (operating result TTM) EBIT $8.67m
Free Cash Flow (TTM) Free Cash Flow $43.23m
Cash position $293.13m
EPS (TTM) EPS $0.61
P/E forward negative
P/S forward 1.91
EV/Sales forward 0.99
Short interest 6.34%
Show more

Is Castle Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Castle Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

Buy
100%

Financial data from Castle Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
332 332
51% 51%
100%
- Direct Costs 73 73
32% 32%
22%
259 259
58% 58%
78%
- Selling and Administrative Expenses 183 183
10% 10%
55%
- Research and Development Expense 51 51
4% 4%
15%
25 25
144% 144%
7%
- Depreciation and Amortization 16 16
30% 30%
5%
EBIT (Operating Income) EBIT 8.67 8.67
113% 113%
3%
Net Profit 18 18
132% 132%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Castle Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Castle Biosciences Inc Stock News

Neutral
GlobeNewsWire
one day ago
Consistent with prior studies, published results from Castle's DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression 1,2 As of the last follow-up, all of the pa...
Neutral
GlobeNewsWire
3 days ago
Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
Neutral
GlobeNewsWire
7 days ago
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pa...
More Castle Biosciences Inc News

Company Profile

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Head office United States
CEO Derek Maetzold
Employees 761
Founded 2007
Website www.castlebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today